Kairos Pharma extends equity line with Helena, presents ENV-105 data at Houston conference

Kairos Pharma, Ltd. disclosed in an 8-K filed for the period ending November 3, 2026 that it has made three amendments to its existing equity line of credit agreement with Helena Global Investment Opportunities I Ltd. The underlying agreement, dated November 12, 2024, established an equity line of credit between the two parties.¹

On February 4, 2026, the companies executed a first amendment adjusting the purchase price to 97% of the average daily VWAP during the pricing period.¹ On October 26, 2026, a second amendment shortened the applicable pricing period from three trading days to one trading day.¹ Then on October 29, 2026, the company entered into a third amendment extending the option to use the equity line of credit for an additional year, through December 31, 2028.¹ Kairos said the three amendments together constitute a material change to the purchase agreement.¹

Separately, the filing disclosed company news from a scientific conference. On November 3, 2026, Kairos issued a press release announcing that its President and Chief Scientific Officer, Neil Bhowmick, was presenting interim efficacy data from the company's ongoing clinical trials of ENV-105 (carotuximab) at a cancer research and drug development conference hosted by the United Scientific Group in Houston, Texas, held that same day.¹ The slide presentation and an accompanying press release were furnished as exhibits to the filing.¹

The 8-K was signed by Kairos CEO John S. Yu. The company noted that the information disclosed under Item 8.01, including the conference presentation and press release, is being furnished rather than filed under the Securities Exchange Act.¹